A drug designed to interrupt a specific inflammation signal in the body reduced measurable signs of that inflammation in a midstage clinical trial. Biomarkers, the proteins used to track whether inflammation is active inside a patient, fell consistently among participants, and higher doses produced greater drops. The drug is called pacibekitug; Novartis recently acquired it, and the results were presented Saturday at the European Society of Cardiology's annual meeting in Munich.
What the TRANQUILITY data show
The study's name is the Phase 2 TRANQUILITY trial. Phase 2 is the midstage test that asks whether a drug is working at the right dose; Phase 1 only establishes whether it is safe. TRANQUILITY found that pacibekitug is having a measurable biological effect. Investigators reported sustained decreases in inflammation biomarkers across participants. Sustained is the key word: a brief dip in a marker that quickly rebounds is less meaningful than a decrease that holds.
The reductions were also dose-dependent. Higher doses led to greater reductions across certain measures, a pattern researchers treat as evidence the drug is the cause of the drop, not some other variable.
Pacibekitug is an antibody that targets interleukin-6, abbreviated IL-6. Interleukin-6 is a protein involved in regulating immune responses. Novartis acquired the drug recently. Experts at the Munich conference were waiting to hear how the company intends to advance pacibekitug toward a cardiovascular treatment, meaning a therapy aimed at conditions affecting the heart and blood vessels.
The remaining distance
A reduction in inflammation biomarkers is a concrete finding. It is not proof the drug prevents cardiovascular events. That case would require a later-stage trial, one designed around clinical outcomes such as whether patients have fewer heart attacks or strokes, rather than lab measures. Novartis has not yet indicated when or whether that step is coming.
The TRANQUILITY results give Novartis a clear biological signal: a drug that reaches its target consistently, with a dose response that held across the measures investigators tracked.